Levi & Korsinsky is investigating whether Altria Group misrepresented the FDA regulatory status of its on! PLUS nicotine pouch and the timing of FDA approvals for other applications. This follows a stock drop after Altria's Q2 2026 results and prior claims that on! PLUS was the only product authorized under the FDA pilot program. The investigation focuses on whether Altria's public statements were misleading about the FDA review process and timing, potentially violating securities laws. Shareholders who suffered losses are encouraged to submit information for evaluation.
Steven Fiorillo's Dividend Harvesting Portfolio has grown to $40,536, delivering a 7.87% yield and generating $7,293 in income since inception, with a 43.25% return on investment. Market optimism driven by big tech earnings and AI advancements encour...
Altria Group is set to announce its 56th consecutive annual dividend increase in August, with a predicted rise of 3.7% to 4.7%, bringing dividends to $4.40–$4.44 per share. Despite ongoing declines in cigarette sales, Altria is transforming its busin...
